It is common for dogs to have internal parasites that cause persistent scratching or unexplained weight loss. Worm infections in dogs are more common than most pet owners know and finding a viable remedy that works against numerous parasites at the same time has been a problem in veterinary care for a long time. That's why afoxolaner and milbemycin oxime chewable tablets are among of the most effective oral choices available today. They provide dual-action protection against external and interior parasites with only one dosage a month.
This page discusses what these chewable pills accomplish, including the particular worm species they target, the science behind the antiparasitic process, and how they fit into a realistic deworming program for dogs.
Afoxolaner And Milbemycin Oxime Chewable Tablets
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablet
9.375+1.875mg：2-3.5kg
18.75+3.75mg：＞3.5-7.5kg
37.5+7.5mg：＞7.5-15kg
75+15mg：＞15-30kg
150+30mg：＞30-60kg
(3)Ointment
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-117
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Which Worms Can Afoxolaner and Milbemycin Oxime Chewable Tablets Target?
The Internal Parasite Coverage You Should Know About
Not all dewormers are the same. Some treatments only cover a limited spectrum of parasites, putting dogs at risk from additional parasites. Afoxolaner and milbemycin oxime chewable tablets are much more potent. They include milbemycin oxime, a macrolide antiparasitic chemical, which has been shown to be effective against a number of species of worms.
The parasites included include heartworms (larvae of Dirofilaria immitis), roundworms (Toxocara canis), hookworms (Ancylostoma caninum, Uncinaria stenocephala), and whipworms (Trichuris vulpis). Milbemycin oxime is an important therapeutic therapy for prevention of heartworm illness.
It has been established in published studies in veterinary pharmacology that milbemycin oxime is >99% effective against Dirofilaria immitis L3 and L4 larvae when administered within 30 days of exposure.
Why Broad-Spectrum Coverage Matters for Dogs
Dogs often have more than one parasite at a time, especially if they live outside or in a home with more than one pet. This leaves holes in protection since you are only treating one species of worm but not others. This gap is filled by the dual-component formulation of these tablets, which combine the ectoparasitic activity of afoxolaner with the endoparasitic reach of milbemycin oxime to provide a truly complete antiparasitic profile in a single consumable tablet.
How Do Afoxolaner and Milbemycin Oxime Chewable Tablets Work Against Intestinal Nematodes?
The Mechanism That Disables Worms at the Cellular Level
Milbemycin oxime, an anthelmintic component in afoxolaner and milbemycin oxime chewable tablets, binds to glutamate-gated chloride ion channels of nerve and muscle cells of invertebrates. This binding increases the permeability of the membrane to chloride ions and results in hyper-polarization of the neuromuscular junction . The end effect is permanent paralysis and death of vulnerable nematodes and heartworm larvae.
The composition of milbemycin oxime consists of 2 active fractions: A3 (about 20%) and A4 (about 80%). Peak plasma concentrations of A3 after oral administration are reached in one to two hours with a half-life of approximately 1.6 days.
Peak plasma concentrations of A4 are reached in a similar time frame with a half-life of about 3.3 days.
The overlapping pharmacokinetic profile guarantees continuous antiparasitic efficacy over the monthly dose period.
Why Dogs Tolerate This Mechanism Safely
Safety is a fair issue in mammals when neuromuscular-acting medicines are discussed. Milbemycin oxime has a well known safety margin in dogs, since the blood-brain barrier in healthy dogs is very impermeable to this chemical. And the drug's main target, glutamate-gated chloride channels, aren't present in vertebrates, so the process that disables worms doesn't work in dogs. That selectivity is a major reason why the drug has an excellent veterinary safety record after decades of clinical usage.
Afoxolaner and Milbemycin Oxime Chewable Tablets for Internal Parasite Control in Dogs
Matching the Right Dose to the Right Dog
In veterinary pharmacology, the correct dosage is a must. The afoxolaner and milbemycin oxime chewable tablets come in five different strengths, depending on the weight of the dog, to be sure the dog takes the correct amount of medication. The 9.375 mg afoxolaner + 1.875 mg milbemycin oxime pill is for dogs weighing 2–3.5 kg, while the 150 mg + 30 mg preparation is for dogs in the 30–60 kg range. This tiered technique removes the uncertainty from dividing pills or determining dosages.
For dogs above 50 kg,
it is possible to mix higher specification tablets to achieve the recommended dosage range of 2.5–6.9 mg/kg for afoxolaner and a corresponding proportionate range for milbemycin oxime, always under the direction of a veterinarian.
Special Populations That Require Extra Attention
Some dog populations need a little more care. Dogs with a known MDR1 (ABCG1) gene mutation, most often observed in herding breeds, may have impaired medication metabolism resulting in increased plasma concentrations. Consult with a veterinarian and consider genetic testing before to usage in these breeds. Puppies under 8 weeks of age or weighing less than 2 kg should not be treated with this product.
Clinical safety evidence in these populations is limited and these pills should only be given to pregnant or lactating dogs after the benefit-risk ratio has been examined by a veterinarian.
How Afoxolaner and Milbemycin Oxime Chewable Tablets Fit Into a Dog Deworming Program
Building a Monthly Parasite Prevention Routine
Consistency is the key to effective parasite management. According to veterinary parasitology recommendations, afoxolaner and milbemycin oxime chewable tablets are made for an oral therapy once a month. Taking the pill on the same day each month contributes to uninterrupted therapeutic coverage.
The pill's hue ranges from light crimson to reddish-brown, and it has a texture that dogs would tolerate and is attractively designed for simple administration. It may be taken by hand or combined with meals. Keep out of children's reach. Any leftover material should be put back in its original packing. In humans, accidental intake may cause gastrointestinal discomfort.
Integrating Worm Control With Broader Preventive Care
There is more to deworming than meets the eye. A successful canine health program would include yearly veterinarian visits, environmental cleaning techniques to reduce the risk of reinfection, and routine fecal examination screening for parasites. When compared to intermittent or reactive therapy, the use of chewable tablets containing milbemycin oxime and afoxolaner in this larger practice greatly improves clinical results.
In endemic areas, year-round heartworm prevention is recommended by the Companion Animal Parasite Council (CAPC) and other veterinary parasitology guidelines.
A monthly oral solution that covers both ectoparasites and endoparasites may be convenient and effective for pet owners.
What Makes Afoxolaner and Milbemycin Oxime Chewable Tablets Relevant for Worm Control?
A Dual-Action Formula That Reduces Treatment Complexity
In the past, treating parasites in dogs required a variety of medications to fight fleas, ticks, heartworms, and gastrointestinal worms. This multi-product regimen increased expenses, complicated treatment, and increased the likelihood that doses would be missed. These chewable pills' mixture mix reduces that routine to a single monthly treatment without compromising efficacy against any specific parasite type.
Afoxolaner is a powerful ectoparasiticide that kills fleas and ticks by inhibiting arthropod GABA-gated chloride channels. The range of internal parasites is covered by milbemycin oxime. When used as a whole, they cover a range of parasites that would need two or three different prescription drugs.
Pharmacokinetic Reliability That Supports Monthly Dosing
Pharmacokinetic research on these pills supports demonstrable accuracy of once monthly dosing. Afoxolaner is absorbed orally with a peak plasma concentration occurring within two to four hours, with an absolute bioavailability of 88% and a plasma half-life of roughly two weeks. The prolonged half-life guarantees that protective plasma levels are maintained throughout the whole 30-day dosing period and reduces the window of susceptibility that may be created by shorter acting agents.
Conclusion
Worms in dogs may vary from a minor annoyance to a significant health issue, and need a solution with both depth and dependability to manage them. Afoxolaner and milbemycin oxime chewable tablets are a scientifically proven dual action monthly pill that treats heartworm larvae, gastrointestinal roundworms and ectoparasites in one dose. The pharmacokinetics enable prolonged effectiveness, the weight-based dosage approach promotes accuracy and the appetizing format encourages owner compliance – three features that combined make a major impact in real-world parasite control.
FAQ
Q1: Can afoxolaner and milbemycin oxime chewable tablets be used to prevent heartworms year-round?
+
-
Sure. Milbemycin oxime in the formulation has been shown to be very effective against the larval stages of Dirofilaria immitis when given monthly. This medication is compatible with the regimen of continuous heartworm prevention in endemic regions recommended by veterinary parasitology organizations when used on a regular monthly basis.
Q2: Are these chewable tablets safe for all dog breeds?
+
-
Most breeds have a good safety profile for the tablet. Some herding breeds, especially dogs with the MDR1/ABCB1 gene mutation, may metabolize the milbemycin oxime differently and have higher quantities of the medicine. Breed-specific risk should be considered by a veterinarian before therapy is started. Do not give this product to dogs under the age of 8 weeks or less than 2 kg body weight.
Q3: What should I do if my dog vomits shortly after taking the tablet?
+
-
If vomiting occurs within one to two hours after delivery, the whole therapeutic amount may not be absorbed. Call your veterinarian right away to discuss what to do about a second dose. The pill may be given with a little quantity of food instead than on an empty stomach to help lessen the chance of gastrointestinal distress.
Partner With Bloomtechz for Reliable Afoxolaner and Milbemycin Oxime Chewable Tablets Supply
Since 2008, Bloomtechz is a certified supplier for 24+ International Companies in Pharmaceutical, R&D and Specialty Chemical industries. We have a 100,000 square meter GMP-approved manufacturing facility that is accredited by US FDA, EU, JP and CFDA to guarantee every batch of afoxolaner and milbemycin oxime chewable tablets fulfills stringent quality requirements. We provide 5 weight based specs for dogs from 2kg to 60kg, and OEM/ODM solutions for bespoke applications. Each transaction is backed by triple-link quality verification and a complete refund guaranty on non-conforming purchases. Contact us immediately and let our team design a supply solution that meets your market.
📧 Contact us directly: Sales@bloomtechz.com
References
1. Taenzler, J., Roepke, R. K. L., & Heckeroth, A. R. (2014). Afoxolaner - a new ectoparasiticide for dogs belonging to the isoxazoline class. Veterinary Parasitology, 201(3–4), 173–176.
2. Bowman, D. D., Araiza, M., Lucio-Forster, A., & Leatherbury, M. (2015). Efficacy of milbemycin oxime against Dirofilaria immitis larvae in dogs. Parasites & Vectors, 8, 563.
3. Companion Animal Parasite Council (CAPC). (2022). CAPC Parasite Prevalence Maps and Recommendations for Heartworm Prevention in Dogs. CAPC Publishing.
4. European Medicines Agency (EMA). (2018). Assessment Report: Afoxolaner and Milbemycin Oxime Veterinary Medicinal Product. Committee for Medicinal Products for Veterinary Use, EMA/CVMP.
5. Prichard, R., Ménez, C., & Lespine, A. (2012). Moxidectin and the avermectins: Consanguinity but not identity. International Journal for Parasitology: Drugs and Drug Resistance, 2, 134–153.
6. Wolstenholme, A. J. (2012). Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics. Parasitology, 139(5), 714–723.